Cartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report released on Wednesday morning,Benzinga reports. They currently have a $41.00 price target on the stock. Several other research analysts have also issued reports on the company. BTIG Research initiated coverage on Cartesian Therapeutics in […]